 |
|
|
|
|
Bausch
& Lomb Technolas 217A Excimer Laser System Receives FDA Approval
for the Treatment of Hyperopia with Astigmatism Bausch & Lomb, global leader in refractive laser placements, announced today that its Bausch & Lomb Technolas 217A Excimer Laser System has been approved by the US Food and Drug Administration (FDA) for the correction of hyperopia up to +4.00 diopters and the treatment of astigmatism up to +2.00 diopters when used as part of the LASIK surgical procedure. The increased treatment range means that more patients may potentially benefit from LASIK surgery using the Bausch & Lomb Technolas 217A Excimer Laser System. Approximately 15 percent of people who require vision correction in the United States are farsighted. The Bausch & Lomb Technolas 217A Excimer Laser System is the worldwide leader in laser placements and demonstrated unmatched clinical results when it received initial FDA approval for low/moderate myopia. “This new indication is one more reason why the Bausch & Lomb Excimer laser is the discriminating surgeon’s choice for providing patients exceptional vision correction,” said Robert J. Moore, Bausch & Lomb vice president, Marketing – The Americas Region. “With its expanded treatment range for myopia and its active eye tracking system, this laser has provided exceptional clinical outcomes for patients with myopia.” “I am thrilled with the approval of hyperopia and astigmatism for the Bausch & Lomb Technolas 217A Laser. We have already been able to offer this option to some of our patients with the VISX Star S4 laser. However, the same technology is not right for every patient,” said Dr. Donald Bennett. “Having two different lasers, I am able to choose the right technology for each individual in order to achieve the best results.” |
|
|
|
|||||||||||||||
